Search clinical trials for: 75 mg PF-04991532

Total 329 results

Pfizer

Completed

Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Taiwan, Slovakia, Mexico, Canada, Hungary
Pfizer

Completed

Study Of Safety And Efficacy Of PF-04991532 In Subjects With Type 2 Diabetes Mellitus

Diabetes, Type 2

Canada, United States, Korea, Republic of, Taiwan, Mexico, Hungary, Slovakia
Pfizer

Completed

A 2-week Trial Of PF-04991532 In Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Japan
Danish Head and Neck Cancer Group

Recruiting

DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC. (DAHANCA30)

Hypoxia | Head and Neck Squamous Cell Carcinoma | Radiotherapy | Hypoxic Modification | Gene Profile, Gene Signature

Denmark
Massachusetts General Hospital

Completed

A Controlled Study of Solriamfetol for Attention Deficit Hyperactivity Disorder (ADHD) in Adults

Attention Deficit Hyperactivity Disorder

United States
Shire

Completed

A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)

Crohn's Disease | Ulcerative Colitis

Spain, United States, Korea, Republic of, Lebanon, Australia, Russian Federation, Romania, Hungary, Portugal, Israel, Italy, Turkey, Croatia, Belgium, Bulgaria, Germany, Netherlands, Poland, New Zealand, Argentina, United Kingdom, Greec... and more
Pfizer

Completed

Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of PF-06473871 In Normal Healthy Adults

Healthy

Belgium
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers

Healthy

United States
Pfizer

Completed

A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults

Healthy

United States
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers.

Healthy

United States
Ruijin-Hainan Hospital Shanghai Jiao Tong University...

Recruiting

A Prospective Real World Study of Rimegepant in the Treatment of Migraine

Migraine

China
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers

Healthy

United States
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

ENCOrafenib With Binimetinib in bRAF NSCLC (ENCO-BRAF)

Non Small Cell Lung Cancer | BRAF V600E

France
EMD Serono

Terminated

Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)

Lupus Erythematosus, Systemic

United States, Korea, Republic of, Bulgaria, Argentina, Mexico, Italy, Spain, Philippines, Germany, Czechia, Chile, Poland, Peru, United Kingdom, South Africa, Brazil, Russian Federation
Pfizer

Withdrawn

A Study To Look At Safety And Blood Concentrations After Multiple Doses Of PF-03382792 In Healthy Elderly Individuals

Healthy
Pfizer

Completed

A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients

Cancer

United States
EMD Serono
Merck KGaA, Darmstadt, Germany

Terminated

Atacicept in Multiple Sclerosis Extension Study, Phase II (ATAMS ext)

Relapsing Multiple Sclerosis

Sweden, United States, Czech Republic, Russian Federation, Spain, United Kingdom, Lithuania, Ukraine, Netherlands, Canada, Germany, France, Switzerland, Australia, Belgium, Lebanon, New Caledonia
Pfizer

Completed

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Korea, Republic of, Canada, United States, Australia, United Kingdom, Belgium
Pfizer

Completed

A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young Women

Endometriosis

United States, Belgium
GlaxoSmithKline

Completed

Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral Feed Intolerance

Gastroparesis

Australia
Mayo Clinic
Pfizer

Not yet recruiting

Comparison of Rimegepant and Placebo for Pain in IBS

Irritable Bowel Syndrome

United States
Pfizer

Withdrawn

A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative Colitis

Ulcerative Colitis

United States
Pfizer

Terminated

A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)

Multiple Sclerosis

United States
Novartis

Completed

Efficacy and Safety of Aliskiren 75 mg, 150 mg, and 300 mg in Elderly Patients With Essential Hypertension When Given With a Light Meal in a 8 Week Placebo-controlled Study

Hypertension

Slovakia, Italy, Netherlands, Argentina, Germany, Poland, Czech Republic, Iceland
Pfizer

Completed

Efficacy and Safety Study of Rimegepant for the Acute Treatment of Migraine in Japanese Subjects (Japan Only)

Migraine

Japan
Hepion Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of Rencofilstat in Adult Subjects With NASH F3 (ALTITUDE)

NASH With Fibrosis

United States
EMD Serono

Completed

Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus (ADDRESS II)

Lupus Erythematosus, Systemic

Korea, Republic of, Philippines, Spain, United States, Czechia, Germany, United Kingdom, South Africa, Poland, Argentina, Italy, Chile, Bulgaria, Japan, Brazil, Mexico, Peru, Russian Federation
EMD Serono
Merck KGaA, Darmstadt, Germany

Completed

Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE) (APRIL-SLE)

Lupus Erythematosus, Systemic

United States, Croatia, Bulgaria, France, Korea, Republic of, Poland, Russian Federation, South Africa, Spain, United Kingdom, Germany, Malaysia, Latvia, Lithuania, Ukraine, Argentina, Israel, Netherlands, Greece, Taiwan, Philip... and more
Pfizer

Completed

Single Dose Escalation Study of PF-04360365 In Subjects With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

United States
PHARMENTERPRISES LLC

Not yet recruiting

Study to Evaluate the Efficacy and Safety of XC243 in Patients With Exacerbation of Chronic Cystitis

Cystitis

Russian Federation
Pfizer

Completed

Multiple Dose Study Of PF-05231023 In Adult Subjects Who Have Poor Lipid Control With And Without Type 2 Diabetes Mellitus

Diabetes Melliuts, Type 2

United States
Pfizer

Completed

12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin

Diabetes Mellitus, Type 2

United States, Colombia, Spain, Germany, Sweden, Italy
Sumitomo Pharma Co., Ltd.

Terminated

A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase

Schizophrenia

Japan, Taiwan, China, Philippines
Novartis Pharmaceuticals

Completed

16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis (MEASURE2)

Anklyosing Spondylitis

Germany, Austria, Spain, Switzerland, United Kingdom, United States, Singapore, Russian Federation, Netherlands, Italy, Finland, Czechia, Canada
Pfizer
Biohaven Pharmaceutical Holding Company Ltd.

Active, not recruiting

Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis

Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps

United States
Hoffmann-La Roche
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis

Moderate to Severe Ulcerative Colitis

United States, Australia, Thailand, Poland, Russian Federation, Japan, Colombia, Spain, Turkey, Romania, India, Slovakia, France, Hungary, South Africa, Belgium, Bulgaria, Germany, Italy, Mexico, Serbia, Ukraine, United Kingdom
Pfizer

Completed

Study To Characterize Mass Balance, Absolute Bioavailability, Fraction Absorbed And Pharmacokinetics Of 14C PF-06882961

Healthy Volunteer

Netherlands
Pfizer

Completed

A Study To Evaluate D1 Receptor Occupancy (RO) Following Single Dose of PF-06412562 In Healthy Male Volunteers (PET)

Healthy

Sweden
Pfizer

Completed

A Study To Evaluate The PDE10 Enzyme Occupancy Following A Single Dose Of PF-02545920 In Healthy Male Volunteers (PET)

Healthy

Sweden
Pfizer

Completed

A Healthy Volunteer Trial to Gain Information About the Blood Concentrations of PF-06412562 After Oral Administration of a Modified Release Formulation in Fasted and Fed Conditions

Healthy

Belgium
Pfizer

Terminated

Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease With Motor Fluctuations

United States
Cinclus Pharma Holding AB

Active, not recruiting

Investigate Linaprazan Glurate/Linaprazan in Healthy Subjects

GERD

Slovenia
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

Efficacy and Safety of Atacicept in IgA Nephropathy

IgA Nephropathy

United States, Japan, United Kingdom
Pfizer

Terminated

Pre-Operative Study of PF-4691502 With Letrozole Compared To Letrozole Alone In Patients With Early Breast Cancer

Early Breast Cancer (Phase 2) | Advanced Breast Cancer (Phase 1b)

Spain, Sweden, Italy, Belgium
Pfizer

Completed

A Study Testing A Radioactive Compound Given Through A Vein With And Without The Non-Radioactive Compound, Given By Mouth, To Characterize Tissue Distribution Using Positron Emission Tomography Scanning

Healthy

United States
Pfizer

Completed

A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese

Obesity | Overweight

United States
Yale University
National Institute of Mental Health (NIMH); University of Pennsylvania; Columbia... and other collaborators

Recruiting

A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia

Early Course Schizophrenia Spectrum Disorder

United States
Pfizer

Terminated

Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations

Parkinson Disease

United States, Spain, Canada, France, Japan, Germany
Novartis Pharmaceuticals

Withdrawn

A Study to Evaluate the Effects of Indacaterol Maleate (QAB149) as a New Formulation in the EPIC Test Fixture

Asthma
Vertex Pharmaceuticals Incorporated
Cystic Fibrosis Foundation

Completed

Safety Study of Ivacaftor in Subjects With Cystic Fibrosis

Cystic Fibrosis

United States, Canada, Germany

3

Subscribe